Patterns of Care and Survival in Elderly Patients With Locally Advanced Soft Tissue Sarcoma.


Journal

American journal of clinical oncology
ISSN: 1537-453X
Titre abrégé: Am J Clin Oncol
Pays: United States
ID NLM: 8207754

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 11 9 2019
medline: 25 3 2020
entrez: 11 9 2019
Statut: ppublish

Résumé

The aim of this study was to analyze patterns of care in elderly soft tissue sarcoma (STS) patients and their impact on clinical outcome and treatment-related toxicity. We retrospectively collected data of >65-year-old patients diagnosed with locally advanced STS between 1991 and 2017 in a single institution. The study included 111 patients: 105 (94.6%) patients underwent surgery, associated with preoperative (n=19, 17.1%) or postoperative radiotherapy (n=72, 64.8%). Anthracycline-based chemotherapy was prescribed in 41.4% of patients (n=46). Acute grade ≥3 postoperative radiotherapy-related radiation dermatitis and all grades of chemotherapy-induced neutropenia were significantly correlated to age >80 years (P=0.02) and >70 years (P=0.045), respectively. The mean follow-up was 4.1 years (range, 0.1 to 17.7). Three-year and 5-year local recurrence-free survival were 80.3% and 75.7%, respectively; neither treatment-related nor patient-related characteristics affected local recurrence. Three-year and 5-year distant relapse-free survival were 59.6% and 44.6%, respectively. On multivariate Cox regression, undifferentiated pleomorphic sarcoma histology and Charlson Comorbidity Index >7 were independent factors associated with distant relapse-free survival (P=0.026 and P=0.0001). Overall survival was 62% and 46.6% at 3 and 5 years, respectively. On multivariate Cox regression, surgery and Charlson Comorbidity Index <7 were independent factors associated with overall survival (P=0.006 and P=0.0001). In this study, elderly STS patients receiving a tailored treatment encompassing surgery, radiotherapy, and/or chemotherapy obtained an improved outcome, although caution is advised because of increased toxicity in relation to age. Comorbidities should be considered to offer the best treatment option to this frail patient population.

Identifiants

pubmed: 31503061
doi: 10.1097/COC.0000000000000594
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

749-754

Auteurs

Daniela Greto (D)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Calogero Saieva (C)

Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.

Mauro Loi (M)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Isacco Desideri (I)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Camilla Delli Paoli (C)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Monica Lo Russo (M)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Donato Pezzulla (D)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Maria A Teriaca (MA)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Sara Lucidi (S)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Luca Visani (L)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Francesca Terziani (F)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Emanuela Olmetto (E)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Carlotta Becherini (C)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Pierluigi Bonomo (P)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Giulio Francolini (G)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Domenico A Campanacci (DA)

Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence.

Guido Scoccianti (G)

Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence.

Lorenzo Livi (L)

Departments of Biomedical, Experimental, and Clinical Sciences, Radiation Oncology Unit.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH